InvestorsHub Logo
Followers 45
Posts 7066
Boards Moderated 0
Alias Born 02/05/2008

Re: elbiatcho1 post# 1532

Tuesday, 02/28/2017 1:25:32 PM

Tuesday, February 28, 2017 1:25:32 PM

Post# of 1752
Exelixis, Inc. (EXEL) Rating Lowered to Hold at Stifel Nicolaus

Posted by Oliver Carreras on Feb 28th, 2017

Exelixis, Inc. (NASDAQ:EXEL) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday. They presently have a $22.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential downside of 4.72% from the company’s previous close. The analysts noted that the move was a valuation call.

Several other equities research analysts have also recently commented on EXEL. Cowen and Company reaffirmed an “outperform” rating on shares of Exelixis in a research report on Tuesday, November 8th. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Monday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Saturday, January 28th. Finally, Deutsche Bank AG began coverage on Exelixis in a research report on Thursday, November 3rd. They set a “buy” rating and a $17.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $16.76.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL) traded down 3.38% on Tuesday, reaching $22.31. The company’s stock had a trading volume of 5,116,583 shares. The stock’s market cap is $6.39 billion. The stock has a 50-day moving average of $20.01 and a 200-day moving average of $15.30. Exelixis has a one year low of $3.55 and a one year high of $23.49.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 27th. The biotechnology company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.13. The business had revenue of $77.58 million for the quarter, compared to analysts’ expectations of $64.88 million. During the same period last year, the business earned ($0.19) earnings per share. The company’s quarterly revenue was up 680.7% on a year-over-year basis. On average, analysts predict that Exelixis will post ($0.44) EPS for the current fiscal year.

“Exelixis, Inc. (EXEL) Rating Lowered to Hold at Stifel Nicolaus” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/02/28/exelixis-inc-exel-downgraded-to-hold-at-stifel-nicolaus.html.

In other Exelixis news, Director George A. Scangos sold 204,894 shares of the stock in a transaction dated Wednesday, December 7th. The stock was sold at an average price of $17.81, for a total value of $3,649,162.14. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Gisela Schwab sold 22,000 shares of the stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $16.73, for a total value of $368,060.00. The disclosure for this sale can be found here. In the last three months, insiders sold 604,444 shares of company stock worth $10,413,061. 5.90% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. BlackRock Institutional Trust Company N.A. increased its position in Exelixis by 7.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,770,563 shares of the biotechnology company’s stock worth $73,806,000 after buying an additional 413,100 shares in the last quarter. KCG Holdings Inc. increased its position in Exelixis by 2.2% in the third quarter. KCG Holdings Inc. now owns 130,582 shares of the biotechnology company’s stock worth $1,670,000 after buying an additional 2,780 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Exelixis during the third quarter worth $28,867,000. Rock Springs Capital Management LP purchased a new position in Exelixis during the third quarter worth $1,599,000. Finally, Allianz Asset Management AG increased its position in Exelixis by 30.2% in the fourth quarter. Allianz Asset Management AG now owns 1,091,543 shares of the biotechnology company’s stock worth $16,274,000 after buying an additional 253,123 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.


https://www.chaffeybreeze.com/2017/02/28/exelixis-inc-exel-downgraded-to-hold-at-stifel-nicolaus.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EXEL News